Collectively, our findings identify LCN2, ELANE, CAMP, and CTSG as compelling biomarkers for the evaluation of neurological disability in MS, with LTF offering complementary, though comparatively moderate, predictive value. This evidence concerns the gene CTSG and myeloid sarcoma.